Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U6 small nuclear 1027, pseudogene (RNU6-1027P) is a **pseudogene** derived from the highly conserved U6 small nuclear RNA (snRNA), an essential component of the spliceosome complex responsible for pre-mRNA splicing in eukaryotes[3][6]. Pseudogenes are DNA sequences similar to known genes but are generally non-functional due to mutations or lack of regulatory elements; they may arise via retrotransposition mechanisms such as LINE-1 activity[6]. RNU6-1027P does not encode a functional protein or RNA and is not considered a therapeutic target. In rare cases, small RNAs transcribed from some pseudogenes can exert regulatory effects, including possible local chromatin repression, but such activity is not established for RNU6-1027P specifically[4]. There are no known drug interactions, disease associations, or roles as a biomarker for this pseudogene. **Additional context:** - The parent gene, U6 snRNA, plays a fundamental role in splicing as part of the spliceosomal machinery[1][3]. - U6 pseudogenes are common in vertebrate genomes, typically non-functional, reflecting retrotranspositional activity in genome evolution[6]. - The specific pseudogene RNU6-1027P does not have characterized functional, pathological, or pharmacological significance per current knowledge. - If you seek information about the functional U6 snRNA, not the pseudogene, this would have different biological significance[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 1027, pseudogene (RNU6-1027P).